Nature Medicine

Nature Medicine is an academic journal publishing research articles, reviews, news and commentaries in the biomedical area, including both basic research and early-phase clinical research. Topics covered include cancer, cardiovascular disease, gene therapy, immunology, vaccines, and neuroscience. The journal seeks to publish research papers that demonstrate novel insight into disease processes, with direct evidence of the physiological relevance of the results. Founded in 1995, Nature Medicine is published by the Nature Publishing Group, a division of Macmillan Publishers Ltd, and is one of the rapidly expanding stable of Nature journals. As with other Nature journals, there is no external Editorial Board, with editorial decisions being made by an in-house team, although peer review by external expert referees forms a part of the review process. Nature Medicine is published monthly. Articles are archived online in text and PDF formats; access is by subscription only. Its 2010 impact factor was 25.430, making it the highest-cited research journal in preclinical medicine. It is also among the highest impact of primary (non-review) scientific journals.

Nature Publishing Group
Impact factor
25.430 (2010)
Some content from Wikipedia, licensed under CC BY-SA

Discovery may revolutionise diabetes treatment

Research published in the journal Nature Medicine on Monday by my team provides hope for a new approach to treating type 2 diabetes. In animal models of the disease, our treatment restores natural control of blood sugar.

Nov 06, 2014
popularity0 comments 0

Researchers identify early sign of pancreatic cancer

Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer – an upsurge in certain amino acids that ...

Sep 28, 2014
popularity0 comments 0

Watching the death throes of tumours

A clinical trial due to begin later this year will see scientists observing close up, in real time – and in patients – how tumours respond to new drugs.

Feb 26, 2015
popularity24 comments 0

Caring for blindness: A new protein in sight?

Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. ...

Apr 21, 2015
popularity18 comments 0